Drug intelligence / Profile preview

HY6-F9YTE

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

HY6-F9YTE is a monoclonal antibody developed as part of a panel of anti-fentanyl antibodies intended to combat synthetic opioid intoxication. It has been characterized in preclinical studies alongside related antibodies such as HY6-F9WT, HY6-F9DF215, and HY6-F9DHS. After administration, it demonstrates a serum half-life of 6.9 days in animal studies. The antibody is engineered to specifically bind fentanyl or fentanyl analogues, neutralizing their effects and thus potentially serving as a rescue therapy for synthetic opioid overdose.

Other names: HY6-F9YTEHY-6-F9YTEHY 6-F9YTE

Targets

FCGRT (Neonatal crystallizable fragment receptor)

Beyond the preview

Go deeper on HY6-F9YTE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HY6-F9YTE.

Explore the full profile